Promoting Excellence in Education, Research,
and Patient Care in the Rapidly Evolving
Management of Gastrointestinal Cancer
International Society of
Gastrointestinal Oncology
isgioEstablished 2003
Save the Date for the ISGIO 2017 Conference
The 2017 Gastrointestinal Oncology Conference

The 2017 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will take place October 26-27, 2017 at the Hilton Crystal City in Arlington, VA and will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.

Registration is open.
Thursday, October 26th
8:00AM – 8:05AM Presidential Inauguration
Axel Grothey, MD
8:05AM – 8:10AM Introduction and Welcome From The President
Howard Hochster, MD
Session 1: Pancreatic Cancer
Chairpersons: Michael Choti, MD; Eileen O'Reilly, MD
8:10AM – 8:25AM New Drug Development in Pancreatic Cancer
Philip Philip, MD, PhD
8:25AM – 8:30AM Q & A
8:30AM – 8:45AM Management of Hereditary and High-Risk Patients
Michael Goggins, MD
8:45AM – 8:50AM Q & A
8:50AM – 9:05AM Minimally Invasive Pancreatic Resection: Ready for Primetime?
Shishir Maithel, MD
9:05AM – 9:10AM Q & A
  Debate: Role of Radiation Therapy in the Asymptomatic Patient for Locally Advanced Pancreatic Cancer
9:10AM – 9:20AM Pro: Christopher Willett, MD
9:20AM – 9:30AM Con: Wasif Saif, MD
9:30AM – 9:40AM Panel Discussion
  Case Presentations/Panel Discussion
9:40AM – 9:50AM Case 1: Borderline PDAC with R1 Following Neoadjuvant CT
John Mansour, MD (Mentor) / Mathew Porembka, MD (Fellow)
9:50AM – 10:00AM Case 2: Progression following 2nd Line in Young Patient
Eileen O’Reilly, MD (Mentor) / Imane El Dika, MD (Fellow)
10:00AM – 10:10AM Case 3: Acinar Carcinoma, Localized with Subsequent Recurrence
Daniel Laheru, MD (Mentor) / Mark Yarchoan, MD (Fellow)
10:10AM – 10:20AM Panel Discussion
10:20AM – 10:35AM Break/Posters Available for Viewing
Session 2: Hepatobiliary Cancer
Chairpersons: Michael Choti, MD; Ghassan Abou-Alfa, MD
10:35AM – 10:50AM Updateon the Systemic Treatment of Hepatocellular Carcinoma
Anthony El-Khoueiry, MD
10:50AM – 10:55AM Q & A
10:55AM – 11:10AM Bridge to Transplantation: TACE, Y90, SBRT, or Nothing?
Francis Yao
11:10AM – 11:15AM Q & A
11:15AM – 11:30AM Challenges in the Surgical Management of Hilar Cholangiocarcinoma
Michael Choti, MD
11:30AM – 11:35AM Q & A
  Debate: Optimal Initial Treatment of Locally Unresectable Intrahepatic Cholangiocarcinoma
11:35AM – 11:45AM Systemic Chemo: Milind Javale, MD
11:45AM – 11:55AM Regional Therapy: JF Geschwind, MD
11:55AM – 12:05PM Panel Discussion
12:05PM – 12:15PM Case 1: Resected Node Positive Gallbladder Cancer
Michael Choti (Mentor) / Ibrahim Nassour, MD (Fellow) TBD
12:15PM – 12:25PM Case 2: Large HCC with Minimal Extrahepatic Metastatic Disease
Ghassan Abou-Alfa, MD (Mentor) / Imane El Dika, MD (Fellow)
12:25PM – 12:35PM Panel Discussion
12:35PM – 12:45PM Lunch
12:45PM – 2:00PM  
2:00PM – 2:15PM Break/Posters Available for Viewing
Session 3: Esophageal/Gastric Cancer
Chairperson: David Ilson, MD, PhD
  Debate: Debate: Should Pet Scan Guide Preoperative Therapy in Esophageal Cancer?
2:15PM – 2:25PM Pro: Karyn Goodman, MD
2:25PM – 2:35PM Con: David Ilson, MD, PhD
2:35PM – 2:45PM Panel Discussion
2:45PM – 3:00PM Beyond First Line Therapy of Advanced Gastric Cancer
TBD
3:00PM – 3:05PM Q & A
3:05PM – 3:20PM VEGF Directed Agents in Esophagogastric Cancer
Hope Uronis, MD
3:20PM – 3:25PM Q & A
3:25PM – 3:40PM Immunotherapy in Esophagogastric Cancer
John Marshall, MD
3:40PM – 3:45PM Q & A
  Case Presentation/Panel Discussion
3:45PM – 3:55PM Case 1: Patient with Gastric Cancer with + Peritoneal Cytology on Preop Laparoscopy—Palliate or Operate?
Jaffer Ajani, MD (Mentor) /Fellow TBD
3:55 – 4:05PM Case 2: Should More Chemo be Given Post Op After Preop Therapy for Gastric Cancer?
Weijing Sun, MD (Mentor) / Tala Achkar, MD (Fellow)
4:05PM – 4:15PM Case 3: Should Trastuzumab be Continued into Later Line Chemotherapy?
David Ilson, MD, PhD (Mentor) / Rajiv Agarwal, MD (Fellow)
4:15PM – 4:30PM Panel Discussion
4:30PM Meeting Adjourns
   
Friday, October 27th
Session 4: Hot Topics in Gastrointestinal Oncology
Chairpersons: Axel Grothey, MD
8:10AM – 8:15AM Cellular Therapy for Cancer and Potential Applications to GI Oncology
TBD
8:15AM – 8:20AM Q & A
8:20AM – 8:35AM DNA Methylation: Versatility in Tumor Detection and Site-Prediction
David Ahlquist, MD 
8:35AM – 8:40AM Q & A
8:40AM – 8:55AM Emerging Technologies in Radiation Oncology in the Treatment of GI Cancer: IMRT, SBRT and Protons
Manisha Palta, MD
8:55AM – 9:00AM Q & A
9:00AM – 9:15AM Rationale Surveillance Strategies in GI Malignancies
Tanios Bekaii-Saab, MD
9:15AM – 9:20AM Q & A
Session 5: Localized/Adjuvant Colorectal Cancer
Chairpersons: Jaffer Ajani, MD
9:20AM – 9:35AM Rectal Cancer TNT
Julio Garcia-Aguilar, MD, PhD
9:35AM – 9:40AM Q & A
9:40AM – 9:55AM Beyond First Line and Second Line Therapies of Colorectal Cancer (Including Immunotherapy)
TBD
9:55AM – 10:00AM Q & A
  Debate: The IDEA Trial and Rectal Cancer
10:00AM – 10:10AM Pro: Axel Grothey, MD
10:10AM – 10:20AM Con: TBD
10:20AM – 10:30AM Panel Discussion
10:30AM – 10:45AM Break/Posters Available for Viewing
Session 6: Neuroendocrine Tumors (NET)
Chairpersons: Jonathan Strosberg, MD
10:45AM – 11:00AM Recurrence Rates of Stage I-III Pancreatic and Small Bowel NETs After Potentially Curative Surgical Resection
Mauro Cives, MD
11:00AM – 11:05AM Q & A
11:05AM – 11:20AM Surveillance Guidelines for Stage I-III NETs Treated Operatively
Simron Singh, MD
11:20AM – 11:25AM Q & A
11:25AM – 11:40AM Ga68-DOTATATE Scan: What is its Impact on NET Management
Salvador Borges-Neto, MD
11:40AM – 11:45AM Q & A
  Debate: Somatostatin Receptor Imaging Should be Part of Surveillance Strategy vs. Cross-Sectional Imaging Only
11:45AM – 11:55PM Pro: Salvador Borges-Neto, MD
11:55AM – 12:05PM Con: Brian Morse, MD
12:05AM – 12:10PM Panel Discussion
12:10PM – 12:30PM Overview of New Therapies: 177Lu-DOTATATE and Telotristat Ethyl
Jonathan Strosberg, MD
12:30PM – 12:35PM Q & A
12:35PM – 12:45PM Lunch
   
2:00PM – 2:15PM Break/Posters Available for Viewing
Session 7: Advanced Colon Cancer
Chairpersons: Axel Grothey, MD; Howard Hochster, MD
  Debate: Debate:BRAF V600E CRC - First Line Therapy
2:15PM – 2:25PM Standard Chemotherapy: TBD
2:25PM – 2:35PM Targeted Approaches: Tanios Bekaii-Saab, MD
2:35AM – 2:45PM Panel Discussion
2:45PM – 3:00PM Gene Expression Profiles (CMS) in CRC: Can They Guide Therapy?
John Strickler, MD
3:00PM – 3:05PM Q & A
3:05PM – 3:20PM Optimal Treatment Sequence in mCRC – Making Use of all Options
Axel Grothey, MD
3:20PM – 3:25PM Q & A
3:25PM – 3:40PM Role of HIPEC in the Management of mCRC
James Pingpank, MD
3:40PM – 3:45PM Q & A
  Case Presentation/Panel Discussion
3:45PM – 3:55PM Case 1:What is the Best Curative Treatment Strategy for a Patient with Rectal Cancer and Liver Limited Metastases?
Howard Hochster, MD (Mentor) / Saurin Chokshi, MD (Fellow)
3:55PM – 4:05PM Case 2: Non-Surgical Management of a Patient with Rectal Cancer 
Daniel Haller, MD (Mentor) / Thomas Karasic, MD (Fellow)
4:05PM – 4:15PM Panel Discussion
4:15PM – 4:30PM Meeting Summary
Howard Hochster, MD
4:30PM Meeting Adjourns